APLS
HealthcareApellis Pharmaceuticals, Inc.
$24.87
$-0.99 (-3.83%)
Jan 5, 2026
Price History (1Y)
Analysis
Apellis Pharmaceuticals, Inc. is a biotechnology company operating in the healthcare sector. The company has a significant market presence with a market capitalization of $3.15B and annual revenue exceeding $1 billion at $1.02B. Apellis also employs approximately 705 individuals. The company's financial health indicates strong profitability, as evidenced by gross margin of 59.5%, operating margin of 48.7%, and profit margin of 4.4%. Additionally, the returns on equity (ROE) stand at 14.1% and return on assets (ROA) is 5.1%. Apellis' balance sheet reveals a substantial cash position at $480.23M, though it also carries significant debt of $475.37M. Apellis' valuation can be assessed through its price-to-earnings (P/E) ratio, which stands at 71.06 on a trailing basis and -21.44 on a forward-looking basis. The company's revenue has experienced impressive growth, increasing by 133.0% year-over-year.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About Apellis Pharmaceuticals, Inc.
Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutic compounds to treat diseases with high unmet needs. It offers EMPAVELI for the treatment of paroxysmal nocturnal hemoglobinuria; and SYFOVRE for treating geographic atrophy secondary to age-related macular degeneration and geographic atrophy (GA). The company also develops EMPAVELI to treat C3 glomerulopathy and immune complex membranoproliferative glomerulonephritis, hematopoietic stem cell transplantation-associated thrombotic microangiopathy, focal segmental glomerulosclerosis, and delayed graft function; and APL-3007, a small interfering RNA, or siRNA for the treatment of GA. It has a collaboration and license agreement with Swedish Orphan Biovitrum AB (publ) for development and commercialization of pegcetacoplan; and a collaboration with Beam Therapeutics Inc. focused on the use of Beam's base editing technology to discover new treatments for complement-driven diseases. The company was incorporated in 2009 and is based in Waltham, Massachusetts.
Visit website →Key Statistics
- Market Cap
- $3.15B
- P/E Ratio
- 71.06
- 52-Week High
- $35.57
- 52-Week Low
- $16.10
- Avg Volume
- 2.60M
- Beta
- 0.30
Company Info
- Industry
- Biotechnology
- Exchange
- NMS
- Country
- United States
- Employees
- 705